Direct oral anticoagulants in very elderly and high bleeding risk patients with atrial fibrillation often excluded from oral anticoagulation therapy: a nationwide population-based cohort study
{{output}}
Background and aims: In the Edoxaban Low-Dose for Elder Care Atrial Fibrillation Patients (ELDERCARE-AF) trial, very low-dose edoxaban (15 mg once daily) showed better efficacy and positive net clinical benefit compared to placeb... ...
